Zoetis Receives USDA License for Cytopoint Plus™: The First and Only Long-Acting Monoclonal Antibody Providing 75 Days of Allergic Itch Relief in Dogs with Allergic Dermatitis

Abhay Nayak, Executive Vice President and President, U.S. Commercial Operations at Zoetis

“The license of Cytopoint Plus sets a new benchmark in canine dermatology”

Abhay Nayak, Executive Vice President and President, U.S. Commercial Operations at Zoetis

“As a long-acting monoclonal antibody, Cytopoint Plus gives veterinary health professionals the ability to deliver reliable, sustained relief against allergic itch, and gives pet owners something equally valuable: more time focused on their dog, not their dog’s treatment schedule. This license reflects Zoetis’ enduring commitment to improving the lives of animals and the people who love them.”

Lindsay McKay, DVM, DACVD at Animal Dermatology Group

“Frequent vet clinic visits for treating allergic dermatitis can create scheduling hurdles for busy pet caregivers, which may contribute to missed treatments and flare-ups”

Lindsay McKay, DVM, DACVD at Animal Dermatology Group

“Cytopoint Plus directly addresses this challenge, extending the duration of relief from allergic itch through a manageable, convenient treatment routine.”

Tiffany Tapp, DVM, DACVD at Veterinary Healing Arts

“Affordability is an important consideration in the long-term management of allergic dermatitis, particularly for owners of larger dogs”

Tiffany Tapp, DVM, DACVD at Veterinary Healing Arts

“Cytopoint Plus may help make ongoing care more manageable and potentially more affordable for some families by extending the time between injections, while giving veterinary health professionals another option to consider when developing an individualized treatment plan.”